Bribery claims infect drug companies’ dealings in China
By Andrew Jack and Patti Waldmeir, Financial Times September 23, 2013 4:00 pm
It began as a rumour on a Chinese social media
site in July, but the impact has swiftly spread around the world: allegations that GlaxoSmithKline was the “godfather” of a system of bribery in the country totalling up to $500m.
The corruption claims, which have since expanded to other multinational pharmaceutical companies including Sanofi,
Novartis and Eli Lilly, have created a growing sense of concern among executives, investors and doctors alike.
They raise the prospect of a squeeze in future sales growth, and a repetition of the escalating fines imposed on the industry in the US for illegal marketing and overpricing which have exceeded $30bn over the past two decades, according to Public Citizen, a health watchdog.
Last year, GSK paid a record $3bn to settle claims the US Department of Justice described as including “cash payments disguised as consulting fees, expensive meals, weekend
boondoggles and lavish entertainment”. Abbott paid $1.6bn for illegal marketing of its bipolar disorder drug Depakote,
andJohnson & Johnson paid $181m to settle some claims over marketing of its antipsychotic Risperdal, while the final bill could reach $2.2bn.
Now western companies face accusations in China covering
everything from offering doctors luxurious trips to foreign medical conferences and visits to massage parlours, to payments
disguised as research fees. All remain unproven and only scantily described. The sources are often anonymous – and potentially disgruntled – whistleblowers.
They also come in a country where commissions to doctors are viewed as a necessary way of supplementing low salaries. “If a doctor is paid no commission at all to use a particular drug, no
热门文档